Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Thymalfasin in Metastatic Esophageal Cancer
NCT02545751Phase 2Unknown
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thymosin alpha 1. Primary endpoint: Proportion of patients with tumor responses at 6 months. Status: unknown.
02
Drugs
thymosin alpha 1
Beyond the preview
Go deeper on NCT02545751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545751.